What's new?

Added 21 hours ago Drug news

China’s National Medical Products Administration has accepted an application for the approval of denosumab copy biological HLX 14.- Shanghai Henlius Biotech

China’s National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), has accepted an application for the...

Added 21 hours ago Drug news

FDA accepts Genentech’s NDA for Xofluza for the treatment of influenza in children- Genentech/Roche

Genentech, a member of the Roche Group announced that the FDA has accepted a New Drug Application (NDA) as well...

Added 21 hours ago Drug news

CHMP recommends Zolgensma for the treatment of patients with 5q spinal muscular atrophy . - Novartis

AveXis, a Novartis company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...

Added 21 hours ago Drug news

CHMP recommends Zeposia to treat adult patients with relapsing remitting multiple sclerosis.- BMS

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has...

Added 21 hours ago Drug news

CHMP recommends Cosentyx for the treatment of adult patients with active non-radiographic axial spondyloarthritis. -Novartis

Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a...

Added 21 hours ago Drug news

Sanofi receives positive CHMP opinion for Sarclisa for the treatment of relapsed and refractory multiple myeloma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Sarclisa (isatuximab)....

Added 1 day ago Drug news

FDA approves Zeposia to treat relapsing forms of multiple sclerosis ,including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.-BMS

Bristol-Myers Squibb Company announced that the FDA approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with relapsing forms...